|

SMC Radiation Oncology SABR Cohort for Oligometastasis

RECRUITINGSponsored by Samsung Medical Center
Actively Recruiting
SponsorSamsung Medical Center
Started2025-05-01
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07121335

Summary

The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Performance status (ECOG PS) 0-2
* Diagnosed with metastatic disease
* Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)

Exclusion Criteria:

* Patient with a history of prior radiotherapy to the site planned for SABR
* Patients with concomitant brain metastases

Conditions6

CancerOligometastasisOligoprogressionPatient-Reported Outcomes (PRO)Stereotactic Body Radiation Therapy (SBRT)ctDNA

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.